Frontline Ltd. (FRO)
$
17.55
-1.20 (-6.84%)
Key metrics
Financial statements
Free cash flow per share
-0.8033
Market cap
4.1 Billion
Price to sales ratio
1.9913
Debt to equity
1.6004
Current ratio
1.3867
Income quality
1.4859
Average inventory
0
ROE
0.2088
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Frontline Ltd. is a global shipping company specializing in the seaborne transportation of crude oil and oil products. As of December 31, 2021, it operated a fleet of 70 vessels, further supported by its engagement in the charter, purchase, and sale of vessels. The operating expenses amount to $262,995,000.00 encompassing various operational costs incurred throughout its operations. The company reported an income before tax of $503,254,000.00 showcasing its pre-tax profitability, which underscores its efficient management of resources. Additionally, Frontline Ltd. incurred an interest expense of $302,324,000.00 reflecting its debt servicing obligations. The EBITDA ratio is 0.56 highlighting the company's operational efficiency and effectiveness in maintaining strong profit margins. Moreover, the gross profit stands at $1,044,708,000.00 demonstrating the company's profitability from its core operations and its ability to generate revenue. In the financial landscape, Frontline Ltd. presents an accessible investment opportunity as the stock is affordable at $17.55 making it suitable for budget-conscious investors. The stock has a high average trading volume of 3,047,740.00 indicating strong liquidity, which is essential for trading activities. With a mid-range market capitalization of $3,907,033,650.00 the company is a steady performer within the shipping sector. It is a key player in the Oil & Gas Midstream industry, contributing significantly to the overall market landscape and ensuring stability in volatile markets. Furthermore, it belongs to the Energy sector, driving innovation and growth while adapting to the changing dynamics of the shipping and logistics arena.
Investing in Frontline Ltd. (FRO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Frontline Ltd. stock to fluctuate between $12.40 (low) and $28.83 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-05-29, Frontline Ltd.'s market cap is $3,907,033,650, based on 222,623,000 outstanding shares.
Compared to GE Aerospace, Frontline Ltd. has a Lower Market-Cap, indicating a difference in performance.
Frontline Ltd. pays dividends. The current dividend yield is 7.65%, with a payout of $0.18 per share.
To buy Frontline Ltd. (FRO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FRO. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Frontline Ltd.'s last stock split was 1:5 on 2016-02-03.
Revenue: $2,050,385,000 | EPS: $2.23 | Growth: -24.41%.
Visit https://www.frontline.bm/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $29.39 (2024-05-28) | All-time low: $5.73 (2021-01-29).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Spot tanker rates are expected to have been low in the first quarter of 2025 at FRO, which is scheduled to report earnings on May 23.
globenewswire.com
TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicities No dose reductions required to the standard-of-care therapy with 40 mg and 80 mg TUS dose cohorts CSRC endorsed escalation to 120 mg TUS dosing First patient dosed with 120 mg TUS triplet and enrollment continues SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that the Cohort Safety Review Committee (CSRC) monitoring Aptose's Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 80 mg dose TUS to 120 mg dose TUS based on its favorable review of safety and efficacy data from patients in the first two cohorts of the trial. Dosing of the first subject at the 120 mg TUS dose level has commenced.
zacks.com
Here is how Frontline (FRO) and Grupo Aeroportuario del Centro Norte (OMAB) have performed compared to their sector so far this year.
zacks.com
VZ provides critical unmanned aircraft systems to support the New Orleans Police Department during annual Mardi Gras celebrations.
zacks.com
QFIN, NMRK and FRO made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2025.
zacks.com
Frontline (FRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
HSNGY, FRO and TEF made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 4, 2025.
zacks.com
FRO, IX and UVSP made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 1, 2025.
zacks.com
FRO, SAN and IX made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 1, 2025.
zacks.com
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
See all news